Uematsu Takayoshi, Yuen Sachiko, Kasami Masako, Uchida Yoshihiro
Department of Diagnostic Radiology, Shizuoka Cancer Center Hospital, Naga-Izumi, Shizuoka, Japan.
Breast Cancer Res Treat. 2007 Jul;103(3):269-81. doi: 10.1007/s10549-006-9373-y. Epub 2006 Oct 25.
To prospectively evaluate whether dynamic contrast-enhanced magnetic resonance (MR) imaging findings can help predict the presence of malignancy when screening detected microcalcification lesions, and its contribution to patient management of stereotactic vacuum-assisted breast biopsy (SVAB).
Dynamic contrast-enhanced breast MR imaging was performed when screening 100 detected microcalcification lesions not visualized by ultrasonography with 11-gauge SVAB. Definitive surgery was performed on all patients with the biopsy resulting in the diagnosis of breast cancer or atypical ductal hyperplasia (ADH). Positive predictive values (PPVs) and negative predictive values (NPVs) were calculated on the basis of a BI-RADS (Breast Imaging Reporting and Data System) category and the absence or presence of contrast uptake in the area of microcalcification.
The BI-RADS mammography category correlated with the diagnosis of breast cancer (ADH excluded): category 3 = 7% (4/55); category 4 = 48% (13/27); category 5 = 94% (17/18). After dynamic contrast-enhanced MR imaging, three of four malignancies with BI-RADS mammography category 3 were diagnosed as true positive. Therefore, the PPV of BI-RADS mammography category 3 with MR imaging was 1.8% (1/55). The PPV of contrast uptake of MR imaging was 86% (32/37), significantly higher than the 67% (30/45) PPV of BI-RADS mammography 4 and 5 (P = 0.033). The NPV of BI-RADS mammography 3 was 93% (51/55) versus 97% (61/63) NPV of MR imaging (P = 0.167).
In the evaluation of screening detected microcalcification lesions, dynamic contrast-enhanced breast MR imaging provides additional information with high PPV and NPV, and may therefore offer an alternative to SVAB for women who do not want to undergo SVAB with equivocal findings following full diagnostic mammographic assessment, but breast MR imaging with imperfect PPV and NPV cannot replace SVAB.
Dynamic contrast-enhanced breast MR imaging can demonstrate malignant microcalcifications detected by screening mammography and can be recommended in the evaluation of equivocal microcalcifications prior to SVAB.
前瞻性评估动态对比增强磁共振(MR)成像结果能否在筛查发现微钙化病变时帮助预测恶性肿瘤的存在,及其对立体定向真空辅助乳腺活检(SVAB)患者管理的贡献。
对100例超声未显示的筛查发现的微钙化病变患者进行11号SVAB时,同时行动态对比增强乳腺MR成像。对所有活检诊断为乳腺癌或非典型导管增生(ADH)的患者进行确定性手术。根据乳腺影像报告和数据系统(BI-RADS)分类以及微钙化区域有无对比剂摄取计算阳性预测值(PPV)和阴性预测值(NPV)。
BI-RADS乳腺钼靶分类与乳腺癌诊断相关(排除ADH):3类=7%(4/55);4类=48%(13/27);5类=94%(17/18)。动态对比增强MR成像后,4例BI-RADS乳腺钼靶3类恶性肿瘤中有3例被诊断为真阳性。因此,MR成像时BI-RADS乳腺钼靶3类的PPV为1.8%(1/55)。MR成像对比剂摄取的PPV为86%(32/37),显著高于BI-RADS乳腺钼靶4类和5类的PPV 67%(30/45)(P = 0.033)。BI-RADS乳腺钼靶3类的NPV为93%(51/55),而MR成像的NPV为97%(61/63)(P = 0.167)。
在评估筛查发现的微钙化病变时,动态对比增强乳腺MR成像提供了具有高PPV和NPV的额外信息,因此对于在全面诊断性乳腺钼靶评估后结果不明确而不愿接受SVAB的女性,可能是SVAB的替代方法,但PPV和NPV不完善的乳腺MR成像不能替代SVAB。
动态对比增强乳腺MR成像可显示筛查乳腺钼靶发现的恶性微钙化,可推荐用于SVAB前不明确微钙化的评估。